Tchem | B-cell receptor CD22 |
Comments
Disease | Target Count | P-value |
---|---|---|
osteosarcoma | 7933 | 1.65250372683426E-7 |
posterior fossa group B ependymoma | 1530 | 2.79527712369873E-6 |
Pick disease | 1893 | 1.6212450497905E-4 |
primary Sjogren syndrome | 789 | 2.23784301702872E-4 |
nasopharyngeal carcinoma | 1056 | 2.74043157920254E-4 |
psoriasis | 6685 | 6.08442670553732E-4 |
group 4 medulloblastoma | 1875 | 0.00412035429990923 |
chronic lymphosyte leukemia | 232 | 0.00414041315696697 |
adult high grade glioma | 2148 | 0.00961166474812127 |
progressive supranuclear palsy | 674 | 0.0101674218973994 |
interstitial cystitis | 2299 | 0.011130386690255 |
cutaneous lupus erythematosus | 1056 | 0.0199932155027177 |
Disease | log2 FC | p |
---|---|---|
chronic lymphosyte leukemia | -1.200 | 0.004 |
cutaneous lupus erythematosus | 2.400 | 0.020 |
psoriasis | 1.100 | 0.001 |
osteosarcoma | -2.953 | 0.000 |
group 4 medulloblastoma | -1.300 | 0.004 |
interstitial cystitis | 1.600 | 0.011 |
adult high grade glioma | -1.200 | 0.010 |
posterior fossa group B ependymoma | -1.200 | 0.000 |
primary Sjogren syndrome | 1.200 | 0.000 |
nasopharyngeal carcinoma | -1.400 | 0.000 |
Pick disease | -1.500 | 0.000 |
progressive supranuclear palsy | -1.300 | 0.010 |
Species | Source |
---|---|
Chimp | OMA EggNOG |
Macaque | OMA EggNOG |
Mouse | OMA Inparanoid |
Rat | OMA Inparanoid |
Dog | OMA EggNOG Inparanoid |
Horse | OMA EggNOG Inparanoid |
Cow | OMA EggNOG |
Opossum | OMA EggNOG Inparanoid |
CHEMBL502788
pIC50 6.00
CHEMBL501599
pIC50 6.05
CHEMBL509633
pIC50 6.33
CHEMBL509768
pIC50 6.40
CHEMBL502862
pIC50 6.62
CHEMBL511111
pIC50 6.64
PMID | Text |
---|---|
26507663 | results demonstrate that loss of high affinity CD22 ligands on GC B-cells occurs in both mice and humans through alternative mechanisms, unmasking CD22 relative to naive and memory B-cells |
26379425 | Anti-CD22-magnetic nanoparticles-doxorubicin inhibited the proliferation of Raji cells, significantly increased the uptake of doxorubicin, and induced apoptosis. |
26017478 | MicroRNA-19a and CD22 Comprise a Feedback Loop for B Cell Response in Sepsis. |
25484043 | These results suggest that the in vivo mechanism of non-ligand-blocking epratuzumab may, in part, involve the unmasking of CD22 to facilitate the trans-interaction of B cells with vascular endothelium. |
25182044 | By using integrative genomics and analysing the relationships of COPD phenotypes with SNPs and gene expression in lung tissue, we identified CST3 and CD22 as potential causal genes for airflow obstruction. |
23184497 | study detected the expression of CD22 and CD72 on B cells of myasthenia gravis, compared to multiple sclerosis patient controls and healthy controls y |
23083346 | In the absence of functional CD22, B cells have a "hyperactivated" phenotype, CD22 dysfunction could contribute to the pathogenesis of autoimmune diseases. (Review) |
22986740 | The finding that CD22 is expressed on lung cancer cells is significant in revealing a heretofore unknown mechanism of tumorigenesis and metastasis |
22355053 | Anti-CD22 recombinant immunotoxin moxetumomab pasudotox has activity in relapsed/refractory hairy cell leukemia. |
22017452 | Our study implicates the CD22DeltaE12 genetic defect in the aggressive biology of relapsed or therapy-refractory paediatric B-lineage ALL. |
More... |
MHLLGPWLLLLVLEYLAFSDSSKWVFEHPETLYAWEGACVWIPCTYRALDGDLESFILFHNPEYNKNTSK 1 - 70 FDGTRLYESTKDGKVPSEQKRVQFLGDKNKNCTLSIHPVHLNDSGQLGLRMESKTEKWMERIHLNVSERP 71 - 140 FPPHIQLPPEIQESQEVTLTCLLNFSCYGYPIQLQWLLEGVPMRQAAVTSTSLTIKSVFTRSELKFSPQW 141 - 210 SHHGKIVTCQLQDADGKFLSNDTVQLNVKHTPKLEIKVTPSDAIVREGDSVTMTCEVSSSNPEYTTVSWL 211 - 280 KDGTSLKKQNTFTLNLREVTKDQSGKYCCQVSNDVGPGRSEEVFLQVQYAPEPSTVQILHSPAVEGSQVE 281 - 350 FLCMSLANPLPTNYTWYHNGKEMQGRTEEKVHIPKILPWHAGTYSCVAENILGTGQRGPGAELDVQYPPK 351 - 420 KVTTVIQNPMPIREGDTVTLSCNYNSSNPSVTRYEWKPHGAWEEPSLGVLKIQNVGWDNTTIACAACNSW 421 - 490 CSWASPVALNVQYAPRDVRVRKIKPLSEIHSGNSVSLQCDFSSSHPKEVQFFWEKNGRLLGKESQLNFDS 491 - 560 ISPEDAGSYSCWVNNSIGQTASKAWTLEVLYAPRRLRVSMSPGDQVMEGKSATLTCESDANPPVSHYTWF 561 - 630 DWNNQSLPYHSQKLRLEPVKVQHSGAYWCQGTNSVGKGRSPLSTLTVYYSPETIGRRVAVGLGSCLAILI 631 - 700 LAICGLKLQRRWKRTQSQQGLQENSSGQSFFVRNKKVRRAPLSEGPHSLGCYNPMMEDGISYTTLRFPEM 701 - 770 NIPRTGDAESSEMQRPPPDCDDTVTYSALHKRQVGDYENVIPDFPEDEGIHYSELIQFGVGERPQAQENV 771 - 840 DYVILKH 841 - 847 //
PMID | Year | Title |
---|---|---|
26507663 | 2015 | Unmasking of CD22 Co-receptor on Germinal Center B-cells Occurs by Alternative Mechanisms in Mouse and Man. |
26379425 | 2015 | Novel synthesizing method of pH-dependent doxorubicin-loaded anti-CD22-labelled drug delivery nanosystem. |
26017478 | 2015 | MicroRNA-19a and CD22 Comprise a Feedback Loop for B Cell Response in Sepsis. |
25484043 | 2015 | Extensive crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in human lymphoma cells. |
25218447 | 2014 | Uncovering global SUMOylation signaling networks in a site-specific manner. |
25182044 | 2014 | Genetic regulation of gene expression in the lung identifies CST3 and CD22 as potential causal genes for airflow obstruction. |
23184497 | 2013 | Modulation of B cell regulatory molecules CD22 and CD72 in myasthenia gravis and multiple sclerosis. |
23083346 | 2012 | CD22 and autoimmune disease. |
22986740 | 2012 | CD22 antigen is broadly expressed on lung cancer cells and is a target for antibody-based therapy. |
22355053 | 2012 | Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. |
More... |